Sermorelin vs Teriparatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.
Full details →Side-by-Side Comparison
| Aspect | Sermorelin | Teriparatide |
|---|---|---|
| Dose Range | 100 mcg–300 mcg | 20 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 8–12 weeks | 52–104 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. | Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone. |
| Typical Dosage | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. | 20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies. |
| Administration | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. | Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk. |
| Side Effects | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. | Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible. |
| Best For |
What They Have in Common
Sermorelin, Teriparatide are both commonly used for:
Key Differences
Unique to Sermorelin:
Which Has Stronger Evidence?
- Recovery & Healing: Teriparatide has stronger research support.
| Goal | Sermorelin | Teriparatide |
|---|---|---|
| Recovery & Healing | medium | high |
Key Studies
Sermorelin
- A potentially effective drug for patients with recurrent glioma: sermorelin.
Annals of translational medicine, 2021
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical interventions in aging, 2006
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 1999
Teriparatide
- Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.
JAMA, 2026
- The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis.
The Journal of clinical endocrinology and metabolism, 2025
- Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis.
Journal of bone and mineral metabolism, 2025
Ready to Learn More?
Looking for trusted sources?